Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? - A Cohort Study in a Colombian Population.

Pedro Santos-MorenoSusan MartinezLinda IbataLaura VillarrealFernando Rodríguez-FloridoManuel RiveroAdriana Rojas-VillarragaClaudio Galarza-Maldonado

Published in: Biologics : targets & therapy (2022)

Tofacitinib is an effective treatment option for patients with RA, maybe better after conventional DMARDs than after biologic therapy failure. Further studies are required to determine the role of tofacitinib in different lines of RA treatment and in other groups of patients.

Keyphrases

rheumatoid arthritis
disease activity
end stage renal disease
ejection fraction
newly diagnosed
ankylosing spondylitis
prognostic factors
combination therapy
systemic lupus erythematosus
mesenchymal stem cells
replacement therapy
cell therapy